Updated Cochrane Review Finds Modest Prostate Cancer Mortality Reduction from PSA Screening, But Overdiagnosis Risks Remain
By
Megan Brooks
Summary
An updated Cochrane review finds that PSA screening probably reduces prostate cancer deaths by about 2 per 1000 men screened, a shift from the group's 2013 conclusion that screening did not significantly lower mortality. However, the modest benefit comes with increased diagnoses of localized cancers that may never become clinically significant, highlighting the ongoing trade-off between potential mortality reduction and overdiagnosis risks.
Source
Key quotes
· 3 pulledPSA screening reduces prostate cancer deaths by about 2 per 1000 men screened
The new analysis, based on longer follow-up and additional trial data, suggests that PSA screening reduces prostate cancer deaths
This modest benefit comes at the cost of an increased number of prostate cancer diagnoses, many of which are localized cancers that may never have become clinically significant
You might also wanna read
Prostate cancer screening debate continues as experts seek more accurate detection methods
Prostate cancer screening remains a complex issue. While PSA tests can help detect cancer, widespread screening of asymptomatic men is not r
Meta-analysis: Fiber Reduces Overall Mortality by 23%, Cardiovascular Death by 26%, and Cancer Risk by 22%
A meta-analysis of 64 studies with over 3.5 million subjects found that fiber intake reduces overall mortality by 23%, cardiovascular mortal
Understanding PSA testing: What elevated prostate-specific antigen levels really mean
This article explains PSA (prostate specific antigen) testing for prostate cancer, addressing common confusion around what elevated PSA leve
WHO Analysis: Over a Third of Global Cancer Cases Are Preventable
A WHO analysis reveals that over a third of all cancer cases globally are preventable, with lung, stomach, and cervical cancers accounting f
Examining the Effectiveness and Risks of Full-Body MRI Scans for Cancer Detection
The article examines the growing trend of full-body MRI scans for preventive health screening, exploring both the potential benefits and sig
NHS to offer precision radiotherapy for prostate cancer, cutting treatment from 20 to 5 sessions
The NHS in England is rolling out precision radiotherapy (stereotactic ablative radiotherapy/SABR) for prostate cancer, reducing treatment s
Comments
Sign in to join the conversation.
No comments yet. Be the first.
